颅内后循环动脉瘤的血管内介入治疗

目的总结颅内后循环动脉瘤的特点,探讨其血管内介入治疗的临床疗效。方法回顾性分析40例行血管内介入治疗的颅内后循环动脉瘤患者的临床和影像学资料、介入治疗过程,观察期效果及术后随访结果。结果 40例患者共发现42个后循环动脉瘤,均完成血管内介入治疗,其中8个行单纯弹簧圈栓塞,28个行支架辅助栓塞,1个行Onyx胶栓塞,5个动脉瘤及载瘤动脉同时闭塞。术后即刻DSA造影显示动脉瘤完全栓塞30个,近全栓塞6个,部分栓塞6个。术后6个月随访DSA造影显示动脉瘤完全栓塞36个,近全栓塞4个,部分栓塞1个。患者出院时行改良Rankin量表(mRS)评分,0分35例,1分3例,2分1例,1例死亡为6分;出院后3~6个月随访mRS评分0分38例,1分1例,无动脉瘤复发及新发神经功能障碍病例。结论颅内后循环动脉瘤具有特殊的临床与影像学表现,且复杂动脉瘤较为常见,对于颅内后循环动脉瘤,血管内介入治疗是一种安全有效的治疗方法。     

闭环支架半释放技术在颅内宽颈动脉瘤血管内介入治疗中的应用

目的 探讨闭环支架半释放技术在弹簧圈栓塞颅内宽颈动脉瘤治疗中的安全性和有效性。方法 回顾性分析2019年12月～2021年1月采用闭环支架半释放技术辅助弹簧圈栓塞治疗37例颅内宽颈动脉瘤的临床和影像学资料。共40个动脉瘤，其中破裂动脉瘤21个，未破裂19个。结果 16个动脉瘤使用LVIS支架，24个动脉瘤使用Enterprise或Enterprise2支架。技术成功率100%(40/40)。术中支架内血栓形成发生率8.1%(3/37)。术后即刻DSA显示RaymondⅠ级32个，Ⅱ级5个，Ⅲ级3个。出院时改良Rankin量表(modified Rankin Scale, mRS)评分0分32例，1分2例，2分3例。37例随访时间6～19个月，平均9.6月。出院后3个月mRS 0分33例，1分2例，2分2例。末次DSA显示RaymondⅠ级31个，Ⅱ级6个，Ⅲ级3个。31个动脉瘤治愈，7个动脉瘤稳定，2个动脉瘤复发。结论 闭环支架半释放技术在颅内宽颈动脉瘤的血管内介入治疗中安全有效。     

支架辅助弹簧圈栓塞治疗大脑中动脉分叉部宽颈动脉瘤

目的 观察支架辅助弹簧圈栓塞治疗大脑中动脉分叉部宽颈动脉瘤的安全性和有效性。方法 分析60例接受支架辅助弹簧圈栓塞治疗的大脑中动脉分叉部宽颈动脉瘤患者共65个动脉瘤,观察术后即刻及随访动脉瘤栓塞程度,评估术后并发症、疗效及安全性。结果 术中2例(2/60,3.33%)动脉瘤破裂出血,4例(4/60,6.67%)支架内血栓形成;术后即刻栓塞程度为RaymondⅠ级50个(50/65,76.92%)、Ⅱ级12个(12/65,18.46%)、Ⅲ级3个(3/65,4.62%)。术后1个月内3例(3/60,5.00%)动脉瘤再出血,2例致死;1例(1/60,1.67%)死于肺栓塞;4例(4/60,6.67%)并发脑梗死。1例术后6个月瘤颈复发,1例术后25个月出现无症状性血管闭塞;末次复查数字减影血管造影显示43个(43/51,84.31%)RaymondⅠ级、8个(8/51,15.69%)Ⅱ级。末次随访,49例(49/57,85.96%)改良Rankin量表评分为0～2分,8例(8/57,14.04%)为3～4分。结论 支架辅助弹簧圈栓塞技术治疗大脑中动脉宽颈动脉瘤安全、有效。     

血管内介入治疗大脑后动脉夹层动脉瘤

目的观察血管内介入治疗大脑后动脉夹层动脉瘤的效果。方法回顾性分析12例接受血管内介入治疗的大脑后动脉夹层动脉瘤患者,评价治疗效果。结果12例大脑后动脉夹层动脉瘤中,P1段2例,P1-P2段2例,P2段6例,P3段2例,均成功实施栓塞治疗;对其中2例单纯以弹簧圈栓塞动脉瘤,8例以弹簧圈闭塞载瘤动脉,2例植入支架。术后即刻行复查造影显示Raymond分级1级10例,2级2例。术后4例诉头痛,经对症治疗后2周内好转;未见动脉瘤破裂出血及脑梗死。随访期间影像学检查均未见动脉瘤复发,无新发神经功能障碍及颅内再次出血;末次随访时改良Rankin量表0分10例,1分1例,2分1例。结论血管内介入治疗大脑后动脉夹层动脉瘤效果较好,且安全性较高。     

个体化血管内介入治疗椎动脉夹层动脉瘤

目的观察个体化血管内介入治疗椎动脉夹层动脉瘤(VADA)的临床效果。方法回顾性分析38例VADA患者(43枚动脉瘤)。其中10例(10枚)动脉瘤破裂出血,对6枚采用动脉瘤填塞及载瘤动脉闭塞术,4枚以单支架辅助弹簧圈栓塞。对未破裂33枚动脉瘤均行载瘤动脉重建术,以单支架辅助弹簧圈栓塞3枚,双支架辅助弹簧圈栓塞25枚,三支架辅助弹簧圈栓塞5枚。结果血管内介入治疗所有43枚VADA均获成功,对28枚实现完全及次全栓塞、15枚实现部分栓塞。术后随访12个月,34例(38枚动脉瘤)接受全程复查,其中21枚治愈、11枚改善、6枚稳定,未见复发,无新发脑出血或脑缺血症状;改良Rankin量表(mRS)评分0～1分30例,2分2例,3分1例,4分1例。结论根据具体情况采用个体化血管内介入治疗VADA安全、有效,且预后较好。     

Lvis支架与Enterprise支架辅助栓塞颅内宽颈动脉瘤的比较

目的比较Lvis支架和Enterprise支架辅助弹簧圈栓塞颅内宽颈动脉瘤的安全性和有效性。方法回顾性比较Lvis或Enterprise支架辅助弹簧圈栓塞颅内宽颈动脉瘤212例(214个动脉瘤),其中Lvis组88例(90个动脉瘤),Enterprise组124例(124个动脉瘤),比较2组动脉瘤栓塞即刻及随访时栓塞程度Raymond分级、围术期并发症、mRS评分。结果 Lvis组置入支架90个,Enterprise组124个。术后即刻DSA:Lvis组RaymondⅠ级77.3%(68/88),Ⅱ级13.6%(12/88),Ⅲ级9.1%(8/88);Enterprise组RaymondⅠ级75.8%(94/124),Ⅱ级15.3%(19/124),Ⅲ级8.9%(11/124),2组比较差异无显著性(Z=-0.214,P=0.830)。术后随访复查DSA:Lvis组RaymondⅠ级90.4%(76/84),Ⅱ级4.8%(4/84),Ⅲ级2.4%(2/84),2例术后6个月复发;Enterprise组RaymondⅠ级72.8%(86/118),Ⅱ级15.3%(18/118),Ⅲ级8.5%(10/118),4例术后6个月复发,2组比较差异有显著性(Z=-3.312,P=0.002)。围手术期支架相关并发症发生率Lvis组11.4%(10/88),与Enterprise组5.6%(7/124)比较无统计学差异(χ~2=2.282,P=0.131)。2组术后6个月mRS评分0～2分Lvis组85.2%(75/88),Enterprise组78.2%(97/124),2组比较差异无显著性(Z=-1.145,P=0.252)。结论 Lvis支架和Enterprise支架辅助弹簧圈栓塞治疗颅内宽颈动脉瘤安全、有效。     

Neuroform Atlas支架在颅内动脉分叉处宽颈动脉瘤栓塞中的应用体会

目的 探讨Neuroform Atlas支架在颅内动脉分叉处宽颈动脉瘤栓塞中的价值。方法 回顾性分析2021年1～9月16例采用Neuroform Atlas支架辅助弹簧圈栓塞治疗颅内动脉分叉处宽颈动脉瘤的临床和影像学资料。动脉瘤位于大脑中动脉分叉处8例，大脑前动脉分叉处4例，大脑前、中动脉分叉处2例，大脑前动脉A2远端分叉处1例，大脑后动脉P2分叉处1例。破裂动脉瘤10例(术前Hunt-Hess分级Ⅰ级6例，Ⅱ级2例，Ⅲ级2例),未破裂动脉瘤6例。结果 均在单一Neuroform Atlas支架辅助下完成栓塞，技术成功率100%。术后即刻造影显示动脉瘤完全闭塞13例，瘤颈残留2例，瘤体残留1例。术中及围手术期未观察到介入操作相关并发症。出院前改良Rankin量表(mRS)0～1分11例，2分3例，3分2例。16例随访时间3～14个月，(7.8±3.2)月。mRS评分0～1分14例，2分1例，3分1例。9例术后3～6个月行DSA,动脉瘤完全闭塞8例，瘤颈残留1例，9例均未见载瘤动脉狭窄或支架内闭塞。结论 Neuroform Atlas支架辅助弹簧圈栓塞治疗颅内动脉分叉处宽颈动脉瘤安全，...     

弹簧圈栓塞治疗颅内微小动脉瘤及中长期随访

目的评价弹簧圈栓塞治疗颅内微小动脉瘤（VSCAs）的有效性及稳定性。方法 19例患者（20枚VSCAs）接受血管内弹簧圈栓塞治疗。对其中9枚动脉瘤使用单纯弹簧圈栓塞,9枚使用支架辅助弹簧圈栓塞,2枚使用球囊辅助弹簧圈栓塞。根据DSA表现,将栓塞程度分为完全栓塞、次全栓塞和部分栓塞。术后进行中长期随访并收集DSA及临床结果。结果所有VSCAs均获成功栓塞。术后即刻DSA显示,20枚VSCAs中5枚为完全栓塞,9枚为次全栓塞,6枚为部分栓塞。1~2年随访DSA示20枚VSCAs均完全栓塞,未发现动脉瘤复发及弹簧圈脱出、移位。临床随访显示所有患者均未出现动脉瘤再次破裂出血及神经系统缺血症状。结论血管内弹簧圈栓塞治疗VSCAs有效、稳定;中长期随访证实次全及部分栓塞的患者可发展为完全栓塞。     

介入栓塞治疗未破裂动脉瘤合并脑动静脉畸形

目的探讨未破裂的动脉瘤合并脑动静脉畸形(BAVM)的介入治疗价值。方法回顾性分析23例未破裂的动脉瘤合并BAVM患者的资料。对所有患者均行介入栓塞治疗,根据Redekop分型,选择介入栓塞方式。对近端、远端血流动力型动脉瘤以弹簧圈栓塞,对团内型动脉瘤以Onyx栓塞剂栓塞。术后1周以格拉斯哥转归评分(GOS)评估治疗效果。术后3~6个月行DSA复查病灶是否复发、有无颅内出血。结果 23例患者共36个病灶,其中BAVM合并团内型动脉瘤8个、近端血流动力型动脉瘤16个、远端血流动力型动脉瘤11个、无关血流动力型动脉瘤1个。以弹簧圈栓塞16个近端血流动力型和10个远端血流动力型动脉瘤;以Onyx栓塞剂栓塞8个团内型动脉瘤;1个远端血流动力型动脉瘤因栓塞困难且动脉瘤形态规整未予栓塞,术后第6天患者死于颅内出血引起的脑疝;1个无关血流动力型动脉瘤因易于外科夹闭未予栓塞。23例中,BAVM完全栓塞7例,未完全栓塞16例。19例术后GOS评分为5分,3例为4分,1例死亡病例未评估。除1例死亡外,余22例DSA术后随访均未见复发,无颅内出血。结论介入栓塞治疗未破裂的动脉瘤合并BAVM较为安全、有效,根据各病灶血流动力学特点制定治疗方案、尽量栓塞所有病灶并积极预防术后出血有助于改善患者预后。     

Pipeline血流导向装置治疗颅内复杂动脉瘤的效果

目的观察Pipeline血流导向装置(PED)治疗颅内复杂动脉瘤的有效性及安全性。方法回顾性分析接受PED治疗的11例颅内复杂动脉瘤患者的临床资料。结果11例患者共12个动脉瘤,植入12枚PED,其中10例植入1枚PED、1例2枚,3个动脉瘤单纯植入PED、9个植入PED联合弹簧圈栓塞;术后立即造影示动脉瘤内对比剂滞留,PED贴壁良好,完全覆盖瘤颈,载瘤动脉通畅。术后1例发生局部急性脑梗死,经治疗后康复。术后随访6~9个月,中位随访时间7.5个月,患者症状均明显缓解或消失,未发现严重并发症,动脉瘤闭塞率75.00%(6/9)。根据O'Kelly-Marotta(OKM)分级:A级0个动脉瘤,B级1个,C级2个,D级9个。改良Rankin评分(mRS):0分10例,1分1例。结论PED治疗颅内复杂动脉瘤的效果及安全性均较好。     

Treatment selection for ruptured aneurysm and outcomes: clipping or coil embolization

The International Subarachnoid Aneurysm Trial has shown that coil embolization achieves a better outcome for aneurysms treatable by either clipping or coil embolization. However, many ruptured aneurysms are hardly treatable by either clipping or coil embolization. Selection of either clipping or coil embolization will affect the treatment outcome for ruptured aneurysms. The relationship between patient selection and treatment outcome in a so-called "regional center hospital" in Japan must be clarified. This study included 113 patients with ruptured intracranial saccular aneurysms measuring less than 10 mm. Selection criteria for coil embolization were principally paraclinoid or posterior circulation aneurysm, Hunt and Hess grade IV or over, and patient age 75 years or older. Other aneurysms were principally treated by clipping. Aneurysms with a dome/neck ratio of less than 1.5, distorted aneurysms, Hunt and Hess grades I-III, patient age 74 years or younger, and middle cerebral artery aneurysm were actively treated by clipping. A few exceptional indications were considered in detail. Low invasiveness coil embolization is better than clipping to obtain good neurological outcome for patients with perforators difficult to dissect, aneurysms difficult to dissect due to previous open surgery, and aneurysms requiring bilateral open surgery, despite the slightly higher rebleeding rate in coil embolization. Overall outcomes were modified Rankin Scale (mRS) 0-2 in 82 of 113 patients (73%) and mRS 3-6 in 31 (27%). Appropriate selection of clipping or coil embolization can achieve acceptable treatment outcomes for ruptured aneurysm.     

Complementary management of partially occluded aneurysms by using surgical or endovascular therapy

OBJECT: The authors present a series of patients in whom partially occluded aneurysms were retreated using complementary surgical or endovascular therapy. METHODS: During a period of 18 months, 301 patients with intracranial aneurysms were treated using either clip application (171 patients) or endovascular embolization with Guglielmi Detachable Coils ([GDCs] 130 patients). Routine posttreatment angiography studies revealed residual aneurysms in 21 of these patients, nine of whom were retreated using an endovascular or surgical method, with a mean treatment latency of 1.2 months. Four patients underwent primary surgical clip application, whereas five patients experienced GDC packing first. Among patients in the surgical group, the residual aneurysm neck was small and total elimination of the aneurysm was achieved by packing in GDCs. In patients in the endovascular group the authors incompletely packed the aneurysm because of its wide neck or fusiform component in two patients, perforation of a very small aneurysm in one patient, and coil dislocation in another patient. Typical coil compaction occurred in one case. Complete clip application was achieved in all patients. There was no complication in any patient due to the second treatment modality. Final outcome was excellent or good in six and fair in three. CONCLUSIONS: Following clip application or endovascular embolization of intracranial aneurysms, the use of complementary surgical or endovascular management is successful and associated with low morbidity.     

Clinical and angiographic outcome of intracranial aneurysms treated with Matrix detachable coils in Chinese patients

BACKGROUND: Aneurysm recurrence is an innate problem in endovascular treatment of aneurysms with coils. A coated coil system named Matrix (Boston Scientific Neurovascular, Fremont, CA), covered with a bioabsorbable polymeric material (polyglycolide/lactide copolymer [PGLA]), was developed to accelerate intraaneurysmal clot organization and fibrosis. The purpose of this study was to evaluate the efficacy and safety of the Matrix detachable coils in patients with intracranial aneurysms and aneurysmal recurrence rate. METHODS: In a regional neurosurgical center in Hong Kong, data of patients undergoing endovascular embolization of intracranial aneurysm was collected. In a 20-month period, 42 patients with 44 aneurysms were treated by endovascular embolization using matrix coils alone or mixed with bare platinum coils. Thirty-four patients presented with ruptured aneurysms, and 8 patients presented with unruptured aneurysms. RESULTS: Twenty-five patients (60%) had 6-month follow-up DSA, and 10 patients (24%) had 18-month follow-up DSA. Seven aneurysm recurrences were identified, amounting to 16% for all aneurysms and 14% for ruptured aneurysms. Four patients were treated by repeated embolization, and 2 patients were treated by microsurgical clipping. Two adverse events due to thromboembolism were noted. One 78-year-old lady with poor-grade subarachnoid hemorrhage treated by partial embolization died from rebleed at day 4. Another patient with partial embolization and spontaneous thrombosis of dorsal wall ICA aneurysm died at 2 months with aneurysm recanalization with rerupture. Twenty-six patients achieved favorable outcome (GOS score 4 or 5) at last follow-up. The aneurysm recurrence rate using bare platinum coils of the same center was 11% and 7% for all aneurysms and ruptured aneurysms, respectively. CONCLUSION: Matrix coil embolization was safe, but there was no reduction in aneurysm recurrence using matrix coils alone or mixed with GDCs, compared with GDCs alone.     

Treatment of ruptured intracranial aneurysms since the International Subarachnoid Aneurysm Trial: practice utilizing clip ligation and coil embolization as individual or complementary therapies

OBJECT: The aim of this study was to analyze the therapeutic decision-making process and outcome in 100 consecutive patients with aneurysmal subarachnoid hemorrhage (SAH) treated since the completion of the International Subarachnoid Aneurysm Trial (ISAT). All patients were evaluated and treated by a neurosurgeon with subspecialty training in both cerebrovascular and neuroendovascular surgery. METHODS: One hundred consecutive patients with aneurysmal SAH who had been admitted within 1 week posthemorrhage and who had been treated using either surgical clip application or endovascular coil embolization were included in this analysis. All patients underwent a uniform perioperative protocol. All surviving patients were given a questionnaire to assess their modified Rankin Scale score (mRS) and to grade themselves at 6 months and 1 year postintervention. The cohort consisted of 73 women and 27 men with a mean age of 57.27 years (range 27-87 years). Twenty-nine percent of the patients had a World Federation of Neurosurgical Societies (WFNS) Grade IV or V SAH. Forty-seven patients underwent direct surgical clip application, 41 endovascular embolization, and 12 a combination of the two procedures. Good functional outcome--indicated by mRS scores of 0 to 2 after at least 6 months--was achieved in 71% of patients. CONCLUSIONS: Data from the ISAT demonstrated a better functional outcome following endovascular embolization in a selected group of patients with aneurysmal SAH. In routine clinical practice, however, a significant number of patients still benefit from direct surgical clip ligation. Excellent functional results can be realized in a complementary clip ligation and coil occlusion practice in which each patient and aneurysm is evaluated and the two treatment modalities are used individually or, when needed, in combination.     

颅内外动脉狭窄合并颅内动脉瘤同期血管内治疗的效果分析

目的探讨同期治疗颅内外动脉狭窄合并颅内动脉瘤的策略及临床效果。方法回顾性分析2013年4月至2018年9月于北京大学第一医院神经外科行同期血管内治疗的15例颅内外动脉狭窄合并颅内动脉瘤患者的临床资料。男性6例,女性9例,年龄(63.9±9.1)岁(范围:43~79岁);动脉狭窄部位共15处,狭窄程度为75%~95%,其中前循环8处,后循环7处;动脉瘤共17个,最大径(5.3±1.2)mm(范围:3~7 mm),其中前循环动脉瘤11个、后循环动脉瘤6个。患者均行同期动脉狭窄支架成形及动脉瘤栓塞术治疗。记录患者围手术期及术后临床症状、影像学资料及并发症情况。结果15处动脉狭窄均成功置入支架(残余狭窄<30%);17个动脉瘤中,10个行单纯弹簧圈栓塞,7个行支架辅助弹簧圈栓塞,均完全栓塞。围手术期1例患者出现轻微脑梗死症状,其余未发生手术相关并发症。术后随访(43.8±8.2)个月(范围:24~85个月),患者术后6~12个月均复查数字减影血管造影,其中2例出现无症状性支架内再狭窄,所有动脉瘤未见复发。截至末次随访时,患者均未出现颅内出血、缺血性卒中等相关症状。结论颅内外动脉狭窄合并颅内动脉瘤应根据血管狭窄的部位、程度及动脉瘤的大小、形态、位置、数量及两者的位置关系等因素综合分析,制定个体化的治疗策略,给予同期血管内治疗可能是一种安全、有效的治疗方法。     

Review of endovascular stent‐assisted embolization for management of intracranial aneurysms

Objective: This was a retrospective review of the results using stent‐assisted coil embolization for management of intracranial aneurysms. Methods: The records of seven patients treated with stent‐assisted Gugliemi detachable coil (GDC) embolization were retrieved from the authors’ prospectively maintained database. The clinical presentation, site and type of aneurysms, treatment procedure and complications, and outcome of these identified cases were reviewed. Results: Between January 2002 and May 2004, seven patients with intracranial aneurysms, four of which were ruptured, were treated by stent‐assisted GDC embolization. Four aneurysms were located at the anterior circulation and three were at the posterior circulation. The indications for stent use were: giant aneurysm (>2.5 cm), dissecting pseudo‐aneurysm, broad‐necked aneurysm and the need for preservation of important parent arteries or branches. Concerning the technical aspect, all except one had successful stent deployment. One stent dislodged after apparent successful deployment. GDC embolization was continued and the aneurysm was partially occluded. More than 90% occlusion of aneurysm sac was achieved in six aneurysms. Intraoperative complications included over‐coagulation, failure in stent deployment, displacement of stent, coil entrapment and thromboembolism. One patient had added focal neurological deficit after the procedure, and one became vegetative due to an unrelated cause. The patient in whom the stent was dislodged suffered another subarachnoid haemorrhage 4 months later and died. Conclusion: Percutaneous intracranial stent is a new and useful device to assist embolization of cerebral aneurysms that were previously not amenable to endovascular therapy. These preliminary results suggest that this procedure could achieve satisfactory outcomes without significant complications.